Skip to content

Study · Randomized controlled trial · n = 2,384 · 2026

4 results

Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials.

Kokkinos A, Thethi T, Lee CJ, Neff LM, Stefanski A, Cao D, Rodriguez A, Bartee A

Diabetes, obesity & metabolism25 Jun 2026Cited by 2 (Europe PMC)

PMID42348366 (opens in a new tab)PMCIDPMC13448863 (opens in a new tab)DOI10.1111/dom.71009 (opens in a new tab)PepBankPUB-42348366
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight treated with tirzepatide, early responders (5% or more weight reduction at Week 8) had significantly greater weight reduction at Week 72 than non-early responders.

    In plain wordsIn adults with obesity treated with tirzepatide, people who lost weight early lost more weight by 72 weeks than people who did not.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight reduction at Week 72 by early response
    Study

    n = 2,384

    Comparator
    Non-early responders (less than 5% weight reduction at Week 8)
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Clinically meaningful weight reduction and improvements in CRPs, including HbA1c, were observed from baseline to Week 72, with significantly greater improvements in ERs compared with non-ERs.
    1 context sentence
    Summary · context
    Post hoc exploratory analyses included tirzepatide-treated participants from SM-1 (n = 1775) and SM-2 (n = 609), categorized as early responders (ERs; ≥ 5% weight reduction) or nonearly responders (non-ERs; < 5% weight reduction) at Week 8.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight treated with tirzepatide, early responders had significantly greater improvements in cardiometabolic risk parameters, including HbA1c, at Week 72 than non-early responders.

    In plain wordsIn adults with obesity treated with tirzepatide, early weight losers had larger improvements in blood sugar and other health markers by 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    MixedCardiometabolic risk parameters including HbA1c at Week 72 by early response
    Study

    n = 2,384

    Comparator
    Non-early responders (less than 5% weight reduction at Week 8)
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Clinically meaningful weight reduction and improvements in CRPs, including HbA1c, were observed from baseline to Week 72, with significantly greater improvements in ERs compared with non-ERs.
    1 context sentence
    Summary · context
    Post hoc exploratory analyses included tirzepatide-treated participants from SM-1 (n = 1775) and SM-2 (n = 609), categorized as early responders (ERs; ≥ 5% weight reduction) or nonearly responders (non-ERs; < 5% weight reduction) at Week 8.
  3. 03HumanRandomized controlled trialSafety outcome

    In adults with obesity or overweight treated with tirzepatide, the pattern, severity and time course of gastrointestinal events were similar between early and non-early responders.

    In plain wordsIn adults with obesity treated with tirzepatide, stomach and bowel side effects were similar in early and non-early weight losers.

    Peptide
    Tirzepatide
    Outcome
    No significant changeGastrointestinal events by early response
    Study

    n = 2,384

    Comparator
    Non-early responders (less than 5% weight reduction at Week 8)
    Analysis
    Exploratory
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    The pattern, severity and time course of gastrointestinal events were similar between groups.
    1 context sentence
    Summary · context
    Post hoc exploratory analyses included tirzepatide-treated participants from SM-1 (n = 1775) and SM-2 (n = 609), categorized as early responders (ERs; ≥ 5% weight reduction) or nonearly responders (non-ERs; < 5% weight reduction) at Week 8.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight treated with tirzepatide, clinically meaningful weight reduction was observed from baseline to Week 72.

    In plain wordsIn adults with obesity treated with tirzepatide, weight went down meaningfully from the start to 72 weeks.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight reduction from baseline to Week 72 in tirzepatide-treated participants
    Study

    n = 2,384

    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Clinically meaningful weight reduction and improvements in CRPs, including HbA1c, were observed from baseline to Week 72, with significantly greater improvements in ERs compared with non-ERs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04657003

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

Eli Lilly and Companyn = 93829 Mar 2021 to 10 Apr 2023

Type 2 Diabetes · Overweight · Obesity

Trial pageClinicalTrials.govUpdated 8 Apr 2024
CompletedPhase 3Results postedNCT04184622

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Eli Lilly and Companyn = 2,5394 Dec 2019 to 6 Jul 2024

Overweight · Obesity

Trial pageClinicalTrials.govUpdated 24 Jul 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.